CD33 and acute myeloid leukemia: Similarly, the anti-E3–anti-CD123 molecule was designed using the same backbone as the CD33-targeting one and served as an additional AML-specific targeting taFv molecule to demonstrate the modularity of the platform (CD123 KD = 32 nM) (Supplementary Fig. 1A and 2A).